KOD · Kodiak Sciences

The thesis

Kodiak Sciences' shares look more likely to lag the S&P 500 than to lead it over the next three months. The shares rose 161.8% in the three months to 12 November 2026, which prices in the DAYBREAK win in wet age-related macular degeneration (wet AMD). Meanwhile the company has started selling new shares to fund itself. The PEAK topline, which Kodiak guides for December 2026, settles the call.

The third-quarter report on 12 November 2026 showed how much cash the company has to work with. Cash and equivalents fell to $88.7 million at 30 September 2026, from $125.9 million at 30 June 2026. The net loss for the quarter was $66.2 million. Kodiak raised $69 million in net proceeds through its at-the-market (ATM) share sales program after the quarter ended, and it still guides that cash lasts only "into 2027" (company results release, 12 November 2026).

The price reflects a company valued at $6.80 billion, according to MarketBeat on 12 November 2026. Kodiak has no approved drug and no product revenue. The rating is Low for three reasons. The DAYBREAK result is already in the price. The ATM sales show that dilution has begun. A second binary trial result falls inside the three-month window.

Bullish and bearish views on Kodiak Sciences Inc

The bull case on Kodiak Sciences Inc (KOD), in brief: both drugs met the primary endpoint. The bear case: share sales have started.

Bull case

• Both drugs met the primary endpoint. On 28 September 2026 Kodiak reported that Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) both gave vision gains no worse than aflibercept (Regeneron's Eylea) at one year. The p-values were 0.0007 and 0.0036 (company 8-K exhibit 99.1).
• Most Zenkuda patients reached six-month dosing. In the same release, 54% of Zenkuda patients reached a six-month dosing interval at year one. Intraocular inflammation was 0% for Zenkuda and 0.4% for tabirafusp-ted.
• The filing is on schedule. On 12 November 2026 Kodiak said it is "on track to submit the multi-indication BLA for Zenkuda by year end." A Biologics License Application (BLA) is the request for FDA approval.
• PEAK is fully enrolled and on time. Enrollment in the first 300-patient PEAK cohort is complete. Topline results "remain on track for a December 2026 release" (third-quarter release, 12 November 2026).
• The largest holder keeps buying. SEC Form 4 filings show Baker Bros. Advisors funds buying 1,941,755 shares on 28 September to 29 September 2026, at average prices of $72.57 to $88.59. They bought another 247,090 shares at $98.51 on 4 November to 5 November 2026.

Bear case

• Share sales have started. Kodiak raised $69 million in net proceeds through ATM sales after 30 September 2026 (company release, 12 November 2026). That followed the automatic registration statement (Form S-3ASR) filed on 20 October 2026, which named no size.
• The cash runway did not lengthen. Cash was $88.7 million at 30 September 2026, and the nine-month net loss was $190.0 million. Even after the ATM proceeds, Kodiak still guides that cash lasts only "into 2027." Its 12 November 2026 release lists substantial doubt about its ability to continue as a going concern as a risk.
• Spending is rising. Research and development expense was $58.3 million in the third quarter of 2026, up from $50.5 million a year earlier. The company attributes the increase to the PEAK, PINNACLE and ALTO studies and to Phase 3 manufacturing.
• The trial showed parity with Eylea. DAYBREAK was a non-inferiority trial, which tests whether a new drug is no worse than the standard treatment. Any commercial edge has to come from longer dosing intervals against an established product.
• An executive sold into the rally. Chief Financial Officer John Borgeson exercised options on 30,000 shares and sold them at an average of $90.01 on 21 October 2026, under a Rule 10b5-1 trading plan (SEC Form 4).

Price setup

The shares trade near the top of their 52-week range. They closed at $108.25 on 12 November 2026, the day of the third-quarter report. That close is 3.6% below the intraday 52-week high of $112.31 set on 11 November 2026. The 52-week closing low was $18.87 on 13 November 2025, and the reference close for the three-month change was $41.35 on 14 August 2026.

Both trend averages sit far below the price. As of 12 November 2026, the 50-day moving average was $75.22 and the 200-day moving average was $45.50, both from adjusted daily closes.

The November rise came without new trial data. The shares climbed from $91.02 on 5 November 2026 to $99.30 on 6 November 2026, the day a Form 4 reported the Baker Bros. purchase. Since 9 November 2026 they have held between $107.10 and $109.34. A close back under $91.02 would undo the November gain. A close above $112.31 would set a new 52-week high.

Catalysts ahead

• 16 November 2026: CEO Victor Perlroth presents at the Jefferies Global Healthcare Conference in London. This is management's first public appearance after the third-quarter report. Any comment on further share sales, a partner or the BLA date affects the funding part of the case.
• 17 November 2026: CEO presents at the UBS Global Biopharma Conference in London. A second venue for updates on launch funding, partnering and the timing of the PEAK readout.
• 1 December 2026: CEO presents at the 9th Annual Evercore Healthcare Conference in Miami. The last scheduled appearance before the guided PEAK topline. It also shows whether the Zenkuda BLA has been filed or is still due by year end.
• ~December 2026 (est.): PEAK Pivotal Analysis 1 (KSI-101) Phase 3 topline in macular edema caused by eye inflammation. A binary trial result inside the three-month window. A win would add a second late-stage asset and test the lag call. A miss would hit shares that rose 161.8% in three months.
• ~31 December 2026 (est.): End of the guided year-end window for the multi-indication Zenkuda BLA submission. A filing on time moves Zenkuda toward an FDA decision. A slip would weaken the timing case and the funding argument.

What would change the view

A daily close above $131.21, about 21% over the 12 November 2026 close, which would show the shares leading the S&P 500. A December 2026 PEAK Pivotal Analysis 1 topline that meets its primary endpoint would also show it.

What it trades with

Kodiak trades with small- and mid-cap biotech risk appetite, and its own trial and filing news drives it far more. Regeneron, maker of Eylea, is the incumbent whose shares fell on the DAYBREAK news on 28 September 2026 (Benzinga). Further Kodiak regulatory progress is read as a negative for Eylea.

Concentrated ownership shapes trading. Baker Bros. Advisors funds held 34.78% of shares outstanding after the 29 September 2026 purchases (SEC Form 4 filings), which limits the free float. Any change in that holding has to be reported to the SEC within two business days. Additional ATM sales add shares to the float.